Variable | 5-year OS rate (%) | P value | 5-year PFS rate (%) | P value |
---|---|---|---|---|
Age (years) | Â | <Â 0.01 | Â | 0.02 |
 ≤ 60 | 66.7 |  | 54.7 |  |
 > 60 | 42.1 |  | 38.8 |  |
Clinical stage | Â | <Â 0.01 | Â | <Â 0.01 |
 I–II | 68.2 |  | 61.7 |  |
 III–IV | 50.7 |  | 38.4 |  |
B symptoms | Â | 0.02 | Â | <Â 0.01 |
 No | 63.8 |  | 54.2 |  |
 Yes | 48.7 |  | 38.7 |  |
Spleen involvement | Â | 0.01 | Â | <Â 0.01 |
 No | 62.4 |  | 53.0 |  |
 Yes | 41.8 |  | 31.4 |  |
IPI | Â | <Â 0.01 | Â | <Â 0.01 |
 < 3 | 64.4 |  | 55.6 |  |
 ≥ 3 | 41.9 |  | 29.6 |  |
LDH (U/L) | Â | <Â 0.01 | Â | <Â 0.01 |
 ≤ 245 | 72.7 |  | 60.1 |  |
 > 245 | 46.2 |  | 39.0 |  |
β2-MG (mg/L) |  | < 0.01 |  | 0.07 |
 ≤ 2.52 | 73.2 |  | 54.6 |  |
 > 2.52 | 42.2 |  | 35.7 |  |
Rituximab | Â | 0.04 | Â | 0.20 |
 Without | 53.1 |  | 46.4 |  |
 With | 71.9 |  | 58.4 |  |
First-line chemotherapy CR | Â | <Â 0.01 | Â | 0.04 |
 No | 49.1 |  | 45.9 |  |
 Yes | 72.2 |  | 57.2 |  |
PD-L1 expression in tumor cells | Â | 0.02 | Â | 0.01 |
 Negative | 67.3 |  | 59.6 |  |
 Positive | 50.0 |  | 39.6 |  |
PD-L1 expression in tumor microenvironment | Â | 0.21 | Â | 0.26 |
 Negative | 62.0 |  | 52.5 |  |
 Positive | 48.9 |  | 39.3 |  |